KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2016 - 2022)

Emergent BioSolutions (EBS) has 11 years of Non-Current Deffered Revenue data on record, last reported at $5.9 million in Q1 2022.

  • For Q1 2022, Non-Current Deffered Revenue fell 88.76% year-over-year to $5.9 million; the TTM value through Mar 2022 reached $5.9 million, down 88.76%, while the annual FY2021 figure was $4.7 million, 91.53% down from the prior year.
  • Non-Current Deffered Revenue reached $5.9 million in Q1 2022 per EBS's latest filing, up from $4.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $85.6 million in Q4 2019 and bottomed at $4.7 million in Q4 2021.
  • Average Non-Current Deffered Revenue over 5 years is $59.0 million, with a median of $62.5 million recorded in 2018.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 327.49% in 2018, then crashed 91.53% in 2021.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $62.5 million in 2018, then skyrocketed by 36.96% to $85.6 million in 2019, then crashed by 35.16% to $55.5 million in 2020, then plummeted by 91.53% to $4.7 million in 2021, then grew by 25.53% to $5.9 million in 2022.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $5.9 million in Q1 2022, $4.7 million in Q4 2021, and $45.3 million in Q3 2021.